Faculty Member: 
TitleVitamin K supplementation and progression of coronary artery calcium in older men and women
Publication TypeJournal Article
Year of Publication2009
AuthorsShea KM, O'Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, Price PA, Williamson MK, Booth SL
JournalThe American Journal of Clinical Nutrition
Date Published06/2009
KeywordsAged, Calcinosis, Calcium, Coronary Angiography, Coronary Vessels, Dietary Supplements, Extracellular Matrix Proteins, Female, Humans, Interleukin-6, Male, Middle Aged, Osteoprotegerin, Postmenopause, Vitamin K, Vitamins, {C-Reactive} Protein, {Calcium-Binding} Proteins, {Double-Blind} Method

Coronary artery calcification {(CAC)} is an independent predictor of cardiovascular disease. A preventive role for vitamin K in {CAC} progression has been proposed on the basis of the properties of matrix Gla protein {(MGP)} as a vitamin K-dependent calcification inhibitor. The objective was to determine the effect of phylloquinone (vitamin K1) supplementation on {CAC} progression in older men and women.

CAC was measured at baseline and after 3 y of follow-up in 388 healthy men and postmenopausal women; 200 received a multivitamin with 500 microg phylloquinone/d (treatment), and 188 received a multivitamin alone (control).

In an intention-to-treat analysis, there was no difference in {CAC} progression between the phylloquinone group and the control group; the mean {(+/-SEM)} changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively. In a subgroup analysis of participants who were > or =85% adherent to supplementation (n = 367), there was less {CAC} progression in the phylloquinone group than in the control group {(P} = 0.03). Of those with preexisting {CAC} {(Agatston} score > 10), those who received phylloquinone supplements had 6% less progression than did those who received the multivitamin alone {(P} = 0.04). Phylloquinone-associated decreases in {CAC} progression were independent of changes in serum {MGP.} {MGP} carboxylation status was not determined.

Phylloquinone supplementation slows the progression of {CAC} in healthy older adults with preexisting {CAC,} independent of its effect on total {MGP} concentrations. Because our data are hypothesis-generating, further studies are warranted to clarify this mechanism. This trial was registered at as NCT00183001.